Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7672969 | 0.86 | MTNR1A (0.51) | MTNR1AMTNR1BMAPTSMN1; SMN2TRPV1 | |
| SCHEMBL15862370 | 0.85 | MTNR1A (0.50) | MTNR1AMTNR1BMAPTSMN1; SMN2BRD4 | |
| SCHEMBL15861760 | 0.84 | TRPV1 (0.53) | MTNR1AMTNR1BMAPTSMN1; SMN2BRD4 | |
| SCHEMBL23116611 | 0.83 | MAPK1 (0.67) | MTNR1AMTNR1BMAPTSMN1; SMN2TRPV1 | |
| SCHEMBL18935522 | 0.80 | MTNR1A (0.51) | MTNR1AMTNR1BSMN1; SMN2BRD4MAPK1 | |
| SCHEMBL7679840 | 0.79 | KMO (0.46) | KMOMAPTSMN1; SMN2BRD4 | |
| SCHEMBL31130021 | 0.79 | MTNR1A (0.44) | MTNR1AMTNR1BDRD2SMN1; SMN2BRD4 | |
| SCHEMBL7679844 | 0.79 | KMO (0.46) | KMOMAPTSMN1; SMN2BRD4 | |
| SCHEMBL3417837 | 0.79 | MTNR1A (0.50) | MTNR1AMTNR1BSMN1; SMN2BRD4TRPV1 | |
| SCHEMBL31637422 | 0.78 | BRD4 (0.44) | MTNR1AMTNR1BDRD2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380238-B1 | FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-30 | — | — | US | disclosed |
| EP-1109784-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012475-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |